Trulicity Cost in Alabama 2026: Cash Price, Medicaid, Insurance and Compounded Options

What Is the Actual Cash Price for Trulicity in Alabama?

Trulicity's manufacturer list price sits at $931 per month across every pen strength in 2026. That figure applies whether you fill at a Walmart in Birmingham, a Walgreens in Huntsville, or an independent pharmacy in Mobile. Cash-pay patients who present no insurance generally pay close to that number at retail, though GoodRx and NeedyMeds discount codes routinely shave 10 to 18% off at specific chains.

The price reflects a single carton of four prefilled pens, one pen per week. Eli Lilly sets the wholesale acquisition cost (WAC) and has not reduced it meaningfully since dulaglutide received FDA approval in September 2014 [1]. Unlike insulin, GLP-1 receptor agonists such as dulaglutide are not included in Lilly's $35-per-month insulin cap program, so the full WAC applies unless a separate savings mechanism is in place.

A practical note for Alabama residents: pharmacy benefit manager (PBM) negotiated prices mean your insured co-pay may be far lower than $931, but the drug's out-of-pocket cost without any coverage can still exceed $11,000 annually. That figure is not hypothetical for the roughly 15% of Alabama adults who remain uninsured, a rate above the national average of 9.6% as of 2023 [2].

The table below summarizes the four most common payment scenarios an Alabama patient encounters:

| Payment scenario | Typical monthly out-of-pocket | |---|---| | No insurance, no discount | $931 | | GoodRx / discount card only | $760, $840 | | Commercial insurance (formulary tier 3) | $80, $250 co-pay | | Lilly savings card (commercial insurance required) | $25, $150 |

Does Alabama Medicaid Cover Trulicity?

Alabama Medicaid does not cover Trulicity for type 2 diabetes as of the 2026 formulary cycle. The Alabama Medicaid Agency places dulaglutide in a non-preferred or excluded status on its preferred drug list (PDL), meaning standard prior-authorization pathways that work in other states are largely unavailable here [3].

This is a meaningful barrier. Alabama has one of the highest rates of diagnosed type 2 diabetes in the country, at roughly 14.3% of adults, and Medicaid enrollment covers a large share of lower-income Alabamians who might otherwise benefit from GLP-1 therapy. The agency's PDL decisions are updated twice yearly. Clinicians who believe a patient has a medically necessary case for coverage can submit an exception request, but approval rates for non-preferred GLP-1 agents through that channel remain low based on published state pharmacy program reports.

Two narrow situations may allow Medicaid reimbursement. First, patients enrolled in an Alabama Medicaid managed care organization (MCO) sometimes have slightly different formularies than fee-for-service Medicaid; verifying directly with the MCO's pharmacy line is worth the call. Second, dual-eligible patients (Medicare and Medicaid) may have Part D coverage for Trulicity through their Medicare plan's stand-alone drug benefit, since Medicare Part D formulary decisions are federally governed and differ from state Medicaid PDLs.

"GLP-1 receptor agonists with demonstrated cardiovascular benefit should be prioritized in patients with type 2 diabetes and established or high-risk cardiovascular disease, regardless of A1C," states the 2024 American Diabetes Association Standards of Care in Diabetes [4]. That guideline language reflects the REWIND trial data but does not compel state Medicaid programs to cover specific agents.

Which Commercial Insurance Plans Cover Trulicity in Alabama?

Coverage depends on your plan's formulary tier, not on geography. Blue Cross and Blue Shield of Alabama, the state's dominant commercial insurer, places dulaglutide on tier 3 (preferred brand) for most employer-sponsored group plans, with co-pays ranging from $80 to $200 per month after the deductible. UnitedHealthcare and Aetna plans sold through Alabama's ACA marketplace vary by metal level and formulary version.

Prior authorization (PA) is common. Most Alabama commercial payers require at least one of the following before approving Trulicity: documentation of a type 2 diabetes diagnosis, an A1C of 7.5% or above, and failure or contraindication to a first-line agent such as metformin. Some plans add a step-therapy requirement that you try a generic SGLT-2 inhibitor or a cheaper GLP-1 such as generic exenatide before approving dulaglutide.

Step-therapy appeals are possible under Alabama law. The Alabama Insurance Commissioner enforces a step-therapy override right for patients whose prescribers document clinical reasons why the required step-through drug is contraindicated or has already failed. Submitting the appeal with the REWIND cardiovascular outcomes data [5] and a letter of medical necessity from the prescriber improves approval odds substantially.

How the Eli Lilly Trulicity Savings Card Works in Alabama

Lilly's savings program (marketed as the Trulicity Savings Card) is the single most powerful cost-reduction tool for commercially insured Alabama patients. Eligible patients pay as little as $25 per month, though the more typical floor is $150 for tier-3 plans with high deductibles. The program covers up to $150 in monthly savings for most commercially insured individuals.

The card is not available to patients using any federal health care program including Medicare, Medicaid, TRICARE, or VA benefits. That exclusion cuts out a large segment of Alabama's population, given that Fort Rucker (now Fort Novosel) and Redstone Arsenal create meaningful TRICARE enrollment in the state.

Enrollment steps are straightforward. Visit Lilly's official savings program page, verify commercial insurance eligibility, and present the card at any participating retail pharmacy. The card integrates with most pharmacy point-of-sale systems. It does not require a separate mail-in rebate. Cards do not expire on a fixed annual cycle but Lilly can change program terms at any time, so confirming current terms before each refill is sensible.

Patients who exhaust the savings card's annual cap, usually set at $1 to 800 in total savings per year, revert to standard co-pay for the remainder of the benefit year. Planning refills around the card's reset date (typically January 1) saves money for patients who are on the drug year-round.

Is Compounded Dulaglutide Legal in Alabama?

Compounded dulaglutide is available through licensed 503A pharmacies in Alabama and through out-of-state 503A compounding pharmacies that ship into Alabama, but the legal and regulatory picture is narrower than it may appear. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed compounding pharmacies to prepare patient-specific medications when there is a valid prescription and a legitimate patient-practitioner relationship [6].

The critical limitation: dulaglutide is not on the FDA's 503A bulks list of approved compounding ingredients. That absence means 503A pharmacies compounding dulaglutide operate in a gray zone. The FDA has generally tolerated compounding of GLP-1 peptides during documented shortage periods, but Trulicity has not been on the FDA drug shortage list since early 2024. Any pharmacy compounding dulaglutide outside a shortage designation does so at regulatory risk, and the FDA has issued warning letters to facilities in this space.

Section 503B outsourcing facilities, which can compound large batches without individual prescriptions, face even stricter limits. Dulaglutide compounding at 503B facilities is not FDA-authorized under current guidance.

For Alabama patients considering this route, the practical advice is direct: verify the compounding pharmacy's state license with the Alabama State Board of Pharmacy (ALBOP) and request a copy of their certificate of analysis for each batch. Prices at compounding pharmacies currently advertising dulaglutide range from roughly $100 to $250 per month, a significant reduction from the $931 list price, but the pharmacokinetic equivalence to branded Trulicity has not been established in peer-reviewed trials.

What Is the Clinical Evidence Behind Trulicity That Justifies Its Cost?

Dulaglutide's clinical value case rests substantially on REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes), a Lancet-published outcomes trial in 9,901 adults with type 2 diabetes followed for a median of 5.4 years [5]. Dulaglutide 1.5 mg weekly reduced the primary composite endpoint of major adverse cardiovascular events (MACE) by 12% relative to placebo (hazard ratio 0.88 to 95% CI 0.79, 0.99, P<0.026). The REWIND population was notably more representative of real-world type 2 diabetes patients than earlier cardiovascular outcomes trials: 69% had no prior cardiovascular event at baseline, meaning the benefit extended into primary prevention.

A1C reduction in REWIND averaged 0.61 percentage points below placebo at one year. That is modest by GLP-1 standards. The AWARD-11 trial (N=1,842) demonstrated that higher doses of 3 mg and 4.5 mg produced mean A1C reductions of 1.6 and 1.6 percentage points respectively from baseline, with dose-dependent weight loss of 4.7 kg and 5.2 kg [7]. These higher doses received FDA approval in 2020 and are available on the same Trulicity pen platform.

"Dulaglutide's once-weekly dosing and the fact that it requires no dose titration in the first few months distinguishes it from some other agents in the class," noted commentary published in Diabetes Care following the REWIND results [8]. For Alabama patients managing type 2 diabetes in settings with limited specialist access, a weekly fixed-dose injection with no titration schedule reduces the burden of therapy and may improve adherence compared to agents requiring up-titration over months.

The FDA-approved label lists nausea, diarrhea, vomiting, abdominal pain, and decreased appetite as the most common adverse effects, each occurring in 5 to 20% of patients in registration trials [1]. Rare but serious risks include pancreatitis, diabetic retinopathy complications, hypoglycemia (primarily when combined with a sulfonylurea or insulin), and a black-box warning for thyroid C-cell tumors based on rodent data (clinical relevance in humans has not been established but use is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2).

Can You Get Trulicity Through Telehealth in Alabama?

Telehealth prescribing of Trulicity is fully legal in Alabama. Dulaglutide is not a controlled substance, so no Drug Enforcement Administration (DEA) special registration is required for telehealth prescribing. The Alabama Board of Medical Examiners permits synchronous telemedicine encounters as a valid basis for prescribing, provided the prescriber establishes a valid patient-physician relationship and documents a clinical assessment.

Alabama passed the Interstate Medical Licensure Compact (IMLC) enabling legislation, which means physicians licensed in IMLC member states can prescribe to Alabama patients via telehealth without a separate Alabama license. That expands the pool of telehealth providers accessible to rural Alabama residents considerably.

Telehealth platforms including HealthRX connect Alabama patients with board-certified endocrinologists and internal medicine physicians who can evaluate appropriateness for Trulicity, complete prior authorization paperwork, and route the prescription to a preferred retail or mail-order pharmacy. Most telehealth visits for GLP-1 evaluation take 20 to 30 minutes. Many platforms also handle the Lilly savings card enrollment on the patient's behalf.

One practical limitation: Alabama's telehealth prescribing rules require that the prescriber have access to sufficient clinical information to make a safe prescribing decision. For Trulicity, that means at minimum a documented A1C, current medication list, and a review of contraindications. Some platforms request labs within the prior 90 days before prescribing.

Comparing Trulicity to Other GLP-1 Options Available in Alabama

Trulicity is one of five GLP-1 receptor agonists widely available by prescription in Alabama in 2026. The cost and clinical comparison matters because insurance formularies in the state favor some agents over others.

Semaglutide (Ozempic, once weekly) is priced at roughly $936/month list and is preferred on several Alabama Blue Cross commercial formularies for type 2 diabetes, making its co-pay sometimes lower than Trulicity's. In the SUSTAIN-6 trial (N=3,297), semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% relative to placebo (HR 0.74 to 95% CI 0.58, 0.95) [9], a larger relative reduction than REWIND, though the trials are not directly comparable.

Exenatide extended-release (Bydureon BCise) became available as a generic in 2024 in some markets. When generic availability reaches Alabama retail pharmacies, it represents the lowest-cost once-weekly GLP-1 option, potentially under $200/month without insurance. Alabama Medicaid has historically been more willing to cover exenatide than dulaglutide, making the generic a meaningful option for Medicaid patients.

Liraglutide (Victoza) is dosed daily rather than weekly. Its list price is comparable to Trulicity at approximately $900/month. Some patients prefer daily dosing because it allows more flexibility in skipping or adjusting doses, though adherence data generally favor once-weekly regimens.

Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, carries a list price near $1,023/month. It produces superior A1C and weight reduction compared to dulaglutide in the SURPASS-2 trial (N=1,879), where tirzepatide 15 mg reduced A1C by 2.30 percentage points versus 1.86 percentage points for semaglutide 1 mg [10]. Alabama commercial formularies vary widely on tirzepatide coverage. The REWIND-equivalent cardiovascular outcomes data for tirzepatide (SURPASS-CVOT) are expected but not yet published as of mid-2025.

For Alabama patients choosing between agents, the decision comes down to three variables: which agent the insurer prefers (lowest co-pay), which agent the prescriber believes best fits cardiovascular risk profile, and tolerance of side effects. Dulaglutide's no-titration-required profile is a genuine differentiator for patients who find up-titration schedules complicated.

Practical Steps to Reduce Your Trulicity Cost in Alabama Right Now

Getting from $931 list price to a manageable monthly cost requires a specific sequence of steps, not just a single coupon.

First, ask your prescriber to run a real-time benefit check at the point of prescribing. Most EHR systems connected to Alabama commercial payers can return an estimated co-pay within seconds. This tells you immediately whether your plan covers Trulicity and at what tier.

Second, if you have commercial insurance and your plan covers Trulicity, enroll in the Lilly savings card before your first fill. Doing this after the fact does not recover money already paid.

Third, if your plan does not cover Trulicity or places it on a non-preferred tier, request a prior authorization with supporting documentation: REWIND trial data, current A1C, and cardiovascular risk factors. Alabama law requires insurers to provide a PA decision within 72 hours for non-urgent cases and 24 hours for urgent cases.

Fourth, if PA is denied, ask your prescriber to initiate a peer-to-peer review call with the insurance company's medical director. Prescriber-to-medical-director calls overturn initial denials in roughly 30 to 40% of cases in published appeals studies [11].

Fifth, patients who remain uninsured or whose PA appeals fail should ask about Lilly's Insulin Value Program patient assistance pathway and the LillyAnswers program. Income-based free drug programs exist for patients below 400% of the federal poverty level. The federal poverty level for a single adult in 2026 is $15,650; 400% of that is $62,600, which captures a meaningful share of Alabama's uninsured population.